Sarepta Therapeutics Inc
SRPT20.080USD
-0.690-3.32%
收盘 06/20, 16:00（美东）报价延迟15分钟
1.97B总市值
8.39市盈率 TTM
关于 Sarepta Therapeutics Inc 公司
Sarepta Therapeutics, Inc. 是一家商业阶段的生物制药公司。该公司致力于通过发现和开发针对核糖核酸 (RNA) 的疗法、基因疗法和其他用于治疗罕见疾病的基因治疗方式来帮助患者。该公司已开发了多种用于治疗杜氏肌营养不良症 (Duchenne) 的获批产品，并正在开发用于治疗一系列疾病和病症的潜在治疗候选药物，包括杜氏肌营养不良症、肢带型肌营养不良症 (LGMD) 和其他神经肌肉和中枢神经系统 (CNS) 相关疾病。该公司已开发并商业化了四种获批的杜氏肌营养不良症治疗产品：EXONDYS 51（eteplirsen）注射液（EXONDYS 51）、VYONDYS 53（golodirsen）注射液（VYONDYS 53）、AMONDYS 45（casimersen）注射液（AMONDYS 45）和ELEVIDYS。其产品线包括约40个处于不同发现、临床前和临床开发阶段的项目。
公司简介
公司代码SRPT
公司名称Sarepta Therapeutics Inc
上市日期Jun 04, 1997
成立日期2013
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
员工数量1372
证券类型Ordinary Share
年结日Jun 04
公司地址215 1st St Ste 415
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142-1213
电话16172744000
网址https://www.sarepta.com/
公司代码SRPT
上市日期Jun 04, 1997
成立日期2013
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Cristin Rothfuss
Cristin Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
19.15K
+38.59%
Mr. Bilal Arif
Mr. Bilal Arif
Executive Vice President , Chief Technical Operations Officer
Executive Vice President , Chief Technical Operations Officer
16.42K
-16.76%
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
业务USD
名称
营收
占比
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
地区USD
名称
营收
占比
United States
1.64B
86.11%
Rest of World
150.25M
7.90%
业务
地区
业务USD
名称
营收
占比
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
股东统计
更新时间: 6月21日 周六
更新时间: 6月21日 周六
持股股东
股东类型
持股股东
持股股东
占比
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
持股股东
持股股东
占比
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
股东类型
持股股东
占比
Investment Advisor
42.91%
Investment Advisor/Hedge Fund
37.22%
Hedge Fund
9.45%
Individual Investor
4.42%
Research Firm
3.31%
Bank and Trust
1.10%
Pension Fund
1.10%
Sovereign Wealth Fund
1.09%
Venture Capital
0.33%
机构持股
更新时间: 1月20日 周一
更新时间: 1月20日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
1045
100.62M
102.55%
-5.73M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
2022Q4
996
84.01M
95.72%
-10.12M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital International Investors
8.70M
8.96%
+2.44M
+38.95%
Dec 31, 2024
The Vanguard Group, Inc.
9.07M
9.34%
+117.52K
+1.31%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.94M
9.21%
+162.26K
+1.85%
Dec 31, 2024
Capital Research Global Investors
5.93M
6.11%
+49.00
+0.00%
Feb 28, 2025
State Street Global Advisors (US)
4.07M
4.19%
-200.90K
-4.70%
Dec 31, 2024
Janus Henderson Investors
4.33M
4.46%
-30.19K
-0.69%
Dec 31, 2024
Barry (Richard J)
3.18M
3.28%
+2.38K
+0.07%
Mar 10, 2025
Avoro Capital Advisors LLC
2.56M
2.63%
--
--
Dec 31, 2024
Wellington Management Company, LLP
2.07M
2.13%
-657.84K
-24.13%
Dec 31, 2024
Farallon Capital Management, L.L.C.
2.87M
2.95%
+285.10K
+11.05%
Dec 31, 2024
查看更多
持股ETF
更新时间: 6月6日 周五
更新时间: 6月6日 周五
机构名称
占比
Global X Genomics & Biotechnology ETF
2.35%
First Trust NYSE Arca Biotechnology Index Fund
2.26%
iShares Neuroscience and Healthcare ETF
1.65%
Tema Neuroscience and Mental Health ETF
1.2%
WisdomTree BioRevolution Fund
0.92%
Harbor Human Capital Factor Unconstrained ETF
0.87%
SPDR S&P Biotech ETF
0.82%
VanEck Biotech ETF
0.74%
Invesco S&P MidCap 400 Pure Growth ETF
0.57%
Direxion Daily S&P Biotech Bull 3X Shares
0.54%
查看更多
Global X Genomics & Biotechnology ETF
占比2.35%
First Trust NYSE Arca Biotechnology Index Fund
占比2.26%
iShares Neuroscience and Healthcare ETF
占比1.65%
Tema Neuroscience and Mental Health ETF
占比1.2%
WisdomTree BioRevolution Fund
占比0.92%
Harbor Human Capital Factor Unconstrained ETF
占比0.87%
SPDR S&P Biotech ETF
占比0.82%
VanEck Biotech ETF
占比0.74%
Invesco S&P MidCap 400 Pure Growth ETF
占比0.57%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.54%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
